Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Valneva, a specialty vaccine company, and Pfizer Inc. today announced a collaboration to develop and commercialize Valneva‚Äôs Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

Read more